inclusion criteria: to be eligible for the study, each participant must satisfy all the following criteria: 1. healthy participants between 18-59 years of age, 2. sign an informed consent document, 3. negative immunoglobulin g (igg) and immunoglobulin m (igm) antibody for covid-19, 4. negative quantitative polymerase chain reaction (qpcr) sars-cov-2 results of nasopharyngeal/sputum samples, 5. able to comply with the study protocol during the study period, 6. negative tests for human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv), 7. body temperature \<37.2 c, 8. body mass index 18-35 kg/m2, 9. normal laboratory levels of whole blood count, alanine transaminase (alt), aspartate transaminase (ast), total bilirubin, urea, creatinine, and fasting blood glucose, 10. good general health (no known disease in the history and physical examination within 14 days prior to the enrolment), 11. female participants who are not pregnant or who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination, 12. male participants who will be able to have appropriate contraception methods for 6 months after vaccination,

inclusion criteria: to be eligible for the study, each participant must satisfy all the following criteria: 1. healthy participants between 18-59 years of age, 2. sign an informed consent document, 3. negative immunoglobulin g (igg) and immunoglobulin m (igm) antibody for covid-19, 4. negative quantitative polymerase chain reaction (qpcr) sars-cov-2 results of nasopharyngeal/sputum samples, 5. able to comply with the study protocol during the study period, 6. negative tests for human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv), 7. body temperature \<37.2 c, 8. body mass index 18-35 kg/m2, 9. normal laboratory levels of whole blood count, alanine transaminase (alt), aspartate transaminase (ast), total bilirubin, urea, creatinine, and fasting blood glucose, 10. good general health (no known disease in the history and physical examination within 14 days prior to the enrolment), 11. female participants who are not pregnant or who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination, 12. male participants who will be able to have appropriate contraception methods for 6 months after vaccination,

inclusion criteria: to be eligible for the study, each participant must satisfy all the following criteria: healthy participants between 18-59 years of age, sign an informed consent document, negative immunoglobulin g (igg) and immunoglobulin m (igm) antibody for covid-19, negative quantitative polymerase chain reaction (qpcr) sars-cov-2 results of nasopharyngeal/sputum samples, able to comply with the study protocol during the study period, negative tests for human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv), body temperature <37.2 c, body mass index 18-35 kg/m2, normal laboratory levels of whole blood count, alanine transaminase (alt), aspartate transaminase (ast), total bilirubin, urea, creatinine, and fasting blood glucose, good general health (no known disease in the history and physical examination within 14 days prior to the enrolment), female participants who are not pregnant or who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination, male participants who will be able to have appropriate contraception methods for 6 months after vaccination,

inclusion criteria: to be eligible for the study, each participant must satisfy all the following criteria: healthy participants between 18-59 years of age, sign an informed consent document, negative immunoglobulin g (igg) and immunoglobulin m (igm) antibody for covid-19, negative quantitative polymerase chain reaction (qpcr) sars-cov-2 results of nasopharyngeal/sputum samples, able to comply with the study protocol during the study period, negative tests for human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv), body temperature <37.2 c, body mass index 18-35 kg/m2, normal laboratory levels of whole blood count, alanine transaminase (alt), aspartate transaminase (ast), total bilirubin, urea, creatinine, and fasting blood glucose, good general health (no known disease in the history and physical examination within 14 days prior to the enrolment), female participants who are not pregnant or who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination, male participants who will be able to have appropriate contraception methods for 6 months after vaccination,

inclusion criteria: to be eligible for the study, each participant must satisfy all the following criteria: 1. healthy participants between 18-59 years of age, 2. sign an informed consent document, 3. negative immunoglobulin g (igg) and immunoglobulin m (igm) antibody for covid-19, 4. negative quantitative polymerase chain reaction (qpcr) sars-cov-2 results of nasopharyngeal/sputum samples, 5. able to comply with the study protocol during the study period, 6. negative tests for human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv), 7. body temperature <37.2 c, 8. body mass index 18-35 kg/m2, 9. normal laboratory levels of whole blood count, alanine transaminase (alt), aspartate transaminase (ast), total bilirubin, urea, creatinine, and fasting blood glucose, 10. good general health (no known disease in the history and physical examination within 14 days prior to the enrolment), 11. female participants who are not pregnant or who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination, 12. male participants who will be able to have appropriate contraception methods for 6 months after vaccination,

inclusion criteria: to be eligible for the study, each participant must satisfy all the following criteria: 1. healthy participants between 18-59 years of age, 2. sign an informed consent document, 3. negative immunoglobulin g (igg) and immunoglobulin m (igm) antibody for covid-19, 4. negative quantitative polymerase chain reaction (qpcr) sars-cov-2 results of nasopharyngeal/sputum samples, 5. able to comply with the study protocol during the study period, 6. negative tests for human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv), 7. body temperature <37.2 c, 8. body mass index 18-35 kg/m2, 9. normal laboratory levels of whole blood count, alanine transaminase (alt), aspartate transaminase (ast), total bilirubin, urea, creatinine, and fasting blood glucose, 10. good general health (no known disease in the history and physical examination within 14 days prior to the enrolment), 11. female participants who are not pregnant or who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination, 12. male participants who will be able to have appropriate contraception methods for 6 months after vaccination,